HDAC9 and neoplasm: HDAC inhibitors are currently under investigation for playing important roles in cancer epigenetic pathways, exhibiting antitumor activity, and decreasing tumor resistance (Basha and Basavarajaiah, 2022; Sun et al., 2022; Contreras-Sanzón et al., 2022).